Results 61 to 70 of about 4,490 (181)

The Nocebo Effect

Annual Review of Pharmacology and Toxicology
Adverse nocebo responses can cause harm to patients and interfere with treatment adherence and effects in both clinic practice and clinical trials. Nocebo responses refer to negative outcomes to active medical treatments in clinical trials or practice that cannot be explained by the treatment's pharmacologic effects.
openaire   +2 more sources

Comparative Effectiveness Analysis of Phase 3 Clinical Trials in Moderately to Severely Active Inflammatory Bowel Disease Reveals Increased Harm From Placebo and Challenges Equipoise

JCC Plus, Volume 1, Issue 5, September 2026.
Across 47 Phase 3 trials in Crohn's disease and ulcerative colitis, placebo exposure was associated with measurable harm. Disease exacerbation events showed the greatest excess risk, with one additional exacerbation occurring for every 8–13 patients assigned to placebo rather than active therapy.
Joëlle St‐Pierre, Zachary D. Fine, Evan N. Fear, Jeremy A. Klein, Natalie K. Choi, David T. Rubin   +5 more
wiley   +1 more source

Placebo–Placebo, Nocebo–Nocebo, Placebo–Nocebo, and Nocebo–Placebo Effects: A Review of Eastern and Western Perspectives

This study examined placebo and nocebo effects, characterized by classical conditioning, operant conditioning, and expectancy effects. The placebo–placebo and nocebo–nocebo effects can be categorized to function independently, including the influence of various factors such as pill color, size, genetics (including other biological factors), branding ...
openaire   +2 more sources

Lost in Translation: Why Biologic Therapies for Intervertebral Disc Degeneration and Low Back Pain Have Not Reached the Clinic (Yet)

JOR SPINE, Volume 9, Issue 3, September 2026.
From preclinical promise to clinical translation in intervertebral disc degeneration (IDD). Robust preclinical evidence supports a range of biologic therapies, with consistent improvements in imaging, extracellular matrix composition, inflammation, and behavior.
Luca Ambrosio, Jordy Schol, Clara Ruiz‐Fernandez, Vincenzo Denaro, Gianluca Vadalà, Daisuke Sakai   +5 more
wiley   +1 more source

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

No Evidence for Seasonal Variations in Fatigue, Sleepiness and Insomnia Symptoms: Spring Fatigue Is a Cultural Phenomenon Rather Than a Seasonal Syndrome

Journal of Sleep Research, Volume 35, Issue 4, August 2026.
ABSTRACT Although not as prominent as in other animals, humans also experience seasonal variations in sleep duration and circadian processes. These variations are likely primarily driven by changes in photoperiod length. Anecdotally, many people report experiencing fatigue and low energy levels, particularly during spring in Germany, Switzerland and ...
Christine Blume, Albrecht Vorster
wiley   +1 more source

Psychological Factors and Treatment Experiences Associated With Chemotherapy Side‐Effect Expectations and Symptom Severity: A Prospective Longitudinal Study

Cancer Medicine, Volume 15, Issue 7, July 2026.
ABSTRACT Background Patients' expectations may influence how chemotherapy side effects are perceived and could contribute to symptom amplification. Psychological distress and prior treatment experiences are assumed to shape these expectations, yet their interplay and impact on side‐effect burden remain unclear.
Miriam Grapp, Kristin Lichtenberg, Marcel Wilhelm, Hans‐Christoph Friederich, Till Johannes Bugaj   +4 more
wiley   +1 more source

Cholecystokinin input from the anterior cingulate cortex to the lateral periaqueductal gray mediates nocebo pain behavior in mice

Nature Communications
The nocebo effect, opposite of the better-known placebo effect, in which anticipation of harm worsens pain and other symptoms, is increasingly thought to be responsible for poor clinical outcomes.
Sandra J. Poulson, Aleksandrina Skvortsova, Fatama Tuz Zahra, Damien C. Boorman, Seyed Asaad Karimi, Lisiê V. Paz, Wanning Cui, Antonietta Mandatori, Jacob Burek, Zahra Siddiqi, Maryam I. Fazili, Shivani R. Gami, Oakley B. Morgan, Mélanie Di Maria, Anton Dinh, Lianfang Liang, Robert Contofalsky, Jeffrey S. Mogil, Loren J. Martin   +18 more
doaj   +1 more source

The impact of contextual factors on nursing outcomes and the role of placebo/nocebo effects: a discussion paper

PAIN Reports, 2019
. Introduction:. Placebo and nocebo effects represent one of the most fascinating topics in the health care field. Objectives:. the aims of this discussion paper were (1) to briefly introduce the placebo and nocebo effects, (2) to elucidate the ...
Alvisa Palese, Giacomo Rossettini, Luana Colloca, Marco Testa   +3 more
doaj   +1 more source

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 81-93, July 2026.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source